{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:27Z","timestamp":1790790207456,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA100707"],"award-info":[{"award-number":["P50 CA100707"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA155258"],"award-info":[{"award-number":["P01CA155258"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA100707"],"award-info":[{"award-number":["P50 CA100707"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA155258"],"award-info":[{"award-number":["P01CA155258"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapeutically targeting CD138, a define multiple myeloma (MM) antigen, is not yet approved for patients. We here developed and determined the preclinical efficacy of VIS832, a novel therapeutic monoclonal antibody (MoAb) with differentiated CD138 target binding to BB4 that is anti-CD138 MoAb scaffold for indatuximab ravtansine (BT062). VIS832 demonstrated enhanced CD138-binding avidity and significantly improved potency to kill MM cell lines and autologous patient MM cells regardless of resistance to current standard-of-care therapies, via robust antibody-dependent cellular cytotoxicity and phagocytosis mediated by NK and macrophage effector cells, respectively. Specifically, CD38-targeting daratumumab-resistant MM cells were highly susceptible to VIS832 which, unlike daratumumab, spares NK cells. Superior maximal cytolysis of VIS832 vs. daratumumab corresponded to higher CD138 vs. CD38 levels in MM cells. Furthermore, VIS832 acted synergistically with lenalidomide or bortezomib to deplete MM cells. Importantly, VIS832 at a sub-optimal dose inhibited disseminated MM1S tumors in vivo as monotherapy (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), and rapidly eradicated myeloma burden in all mice concomitantly receiving bortezomib, with 100% host survival. Taken together, these data strongly support clinical development of VIS832, alone and in combination, for the therapeutic treatment of MM in relapsed and refractory patients while pointing to its potential therapeutic use earlier in disease intervention.<\/jats:p>","DOI":"10.1038\/s41408-020-00378-z","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T11:03:11Z","timestamp":1604487791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo"],"prefix":"10.1038","volume":"10","author":[{"given":"Tengteng","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-6218","authenticated-orcid":false,"given":"Bharat","family":"Chaganty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boopathy","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip A.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wollacott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy","family":"Adari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Feng","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6167-3319","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Babcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Shriver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Myette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-3569","authenticated-orcid":false,"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"378_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat Rev. Dis. Primers 3, 17046 (2017).","journal-title":"Nat Rev. Dis. Primers"},{"key":"378_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ajh.25117","volume":"93","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar, S. V. Multiple myeloma: 2018 update on diagnosis, risk\u2010stratification, and management. Am. J. Hematol. 93, 981\u20131114 (2018).","journal-title":"Am. J. Hematol."},{"key":"378_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim, C. S. et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 32, 252\u2013262 (2018).","journal-title":"Leukemia"},{"key":"378_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrc.2017.63","volume":"17","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn, C. & Morgan, G. J. Evolutionary biology of high-risk multiple myeloma. Nat. Rev. Cancer 17, 543\u2013556 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"378_CR5","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1111\/febs.12111","volume":"280","author":"H Hassan","year":"2013","unstructured":"Hassan, H. et al. Syndecan-1 modulates beta-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS J. 280, 2216\u20132227 (2013).","journal-title":"FEBS J"},{"key":"378_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fonc.2014.00004","volume":"4","author":"D Barbouri","year":"2014","unstructured":"Barbouri, D. et al. Syndecans as modulators and potential pharmacological targets in cancer progression. Front. Oncol. 4, 4 (2014).","journal-title":"Front. Oncol."},{"key":"378_CR7","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-16-0232","volume":"76","author":"DM Beauvais","year":"2016","unstructured":"Beauvais, D. M. et al. Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by synstatinIGF1R inhibits tumor growth. Cancer Res. 76, 4981\u20134993 (2016).","journal-title":"Cancer Res."},{"key":"378_CR8","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1182\/blood-2017-01-761643","volume":"129","author":"MJ McCarron","year":"2017","unstructured":"McCarron, M. J., Park, P. W. & Fooksman, D. R. CD138 mediates selection of mature plasma cells by regulating their survival. Blood 129, 2749\u20132759 (2017).","journal-title":"Blood"},{"key":"378_CR9","doi-asserted-by":"publisher","first-page":"28693","DOI":"10.18632\/oncotarget.4981","volume":"6","author":"MR Akl","year":"2015","unstructured":"Akl, M. R. et al. Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget 6, 28693\u201328715 (2015).","journal-title":"Oncotarget"},{"key":"378_CR10","doi-asserted-by":"publisher","first-page":"26085","DOI":"10.1074\/jbc.M109.018473","volume":"284","author":"YB Khotskaya","year":"2009","unstructured":"Khotskaya, Y. B. et al. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J. Biol. Chem. 284, 26085\u201326095 (2009).","journal-title":"J. Biol. Chem."},{"key":"378_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10585-007-9125-3","volume":"25","author":"RD Sanderson","year":"2008","unstructured":"Sanderson, R. D. & Yang, Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin. Exp. Metastasis 25, 149\u2013159 (2008).","journal-title":"Clin. Exp. Metastasis"},{"key":"378_CR12","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood-2007-04-082495","volume":"110","author":"Y Yang","year":"2007","unstructured":"Yang, Y. et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110, 2041\u20132048 (2007).","journal-title":"Blood"},{"key":"378_CR13","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1182\/blood.V96.9.3139","volume":"96","author":"C Seidel","year":"2000","unstructured":"Seidel, C. et al. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 96, 3139\u20133146 (2000).","journal-title":"Blood"},{"key":"378_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/1024533031000153630","volume":"8","author":"S Aref","year":"2003","unstructured":"Aref, S., Goda, T. & El-Sherbiny, M. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors. Hematology 8, 221\u2013228 (2003).","journal-title":"Hematology"},{"key":"378_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2141.2004.05299.x","volume":"128","author":"NF Andersen","year":"2005","unstructured":"Andersen, N. F. et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br. J. Haematol. 128, 210\u2013217 (2005).","journal-title":"Br. J. Haematol."},{"key":"378_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood.V95.2.388","volume":"95","author":"C Seidel","year":"2000","unstructured":"Seidel, C. et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95, 388\u2013392 (2000).","journal-title":"Blood"},{"key":"378_CR17","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar, S. V., Landgren, O. & Mateos, M. V. Smoldering multiple myeloma. Blood 125, 3069\u20133075 (2015).","journal-title":"Blood"},{"key":"378_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 (2018).","journal-title":"Blood Cancer J."},{"key":"378_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05058-y","volume":"9","author":"N Bolli","year":"2018","unstructured":"Bolli, N. et al. Genomic patterns of progression in smoldering multiple myeloma. Nat. Commun. 9, 3363 (2018).","journal-title":"Nat. Commun."},{"key":"378_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/ajh.21821","volume":"85","author":"K Detweiler-Short","year":"2010","unstructured":"Detweiler-Short, K. et al. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am. J. Hematol. 85, 737\u2013740 (2010).","journal-title":"Am. J. Hematol"},{"key":"378_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11899-016-0305-6","volume":"11","author":"S Sundararajan","year":"2016","unstructured":"Sundararajan, S., Kumar, A., Korde, N. & Agarwal, A. Smoldering multiple myeloma: emerging concepts and therapeutics. Curr. Hematol. Malig. Rep. 11, 102\u2013110 (2016).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"378_CR22","first-page":"JCO.20.00437","volume":"0","author":"M Bustoros","year":"2020","unstructured":"Bustoros, M. et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J. Clin. Oncol. 0, JCO.20.00437 (2020).","journal-title":"J. Clin. Oncol."},{"key":"378_CR23","doi-asserted-by":"crossref","unstructured":"Landgren, C. O. et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia 34, 1840\u20131852 (2020).","DOI":"10.1038\/s41375-020-0718-z"},{"key":"378_CR24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126\u20131137 (2020).","journal-title":"J. Clin. Oncol."},{"key":"378_CR25","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","volume":"15","author":"H Ikeda","year":"2009","unstructured":"Ikeda, H. et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15, 4028\u20134037 (2009).","journal-title":"Clin. Cancer Res."},{"key":"378_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","volume":"19","author":"S Jagannath","year":"2019","unstructured":"Jagannath, S. et al. Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and\/or refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 19, 372\u2013380 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"378_CR27","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.18632\/oncotarget.26792","volume":"10","author":"C Sun","year":"2019","unstructured":"Sun, C. et al. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Oncotarget 10, 2369\u20132383 (2019).","journal-title":"Oncotarget"},{"key":"378_CR28","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","volume":"34","author":"L Xing","year":"2020","unstructured":"Xing, L. et al. A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia 34, 2150\u20132162 (2020).","journal-title":"Leukemia"},{"key":"378_CR29","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai, Y. T. et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123, 3128\u20133138 (2014).","journal-title":"Blood"},{"key":"378_CR30","doi-asserted-by":"publisher","unstructured":"Lin, L. et al. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia https:\/\/doi.org\/10.1038\/s41375-020-0951-5 (2020).","DOI":"10.1038\/s41375-020-0951-5"},{"key":"378_CR31","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai, Y. T. et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112, 1329\u20131337 (2008).","journal-title":"Blood"},{"key":"378_CR32","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1182\/blood-2011-06-364521","volume":"119","author":"YT Tai","year":"2012","unstructured":"Tai, Y. T. et al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 119, 2074\u20132082 (2012).","journal-title":"Blood"},{"key":"378_CR33","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers, M. et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186, 1840\u20131848 (2011).","journal-title":"J. Immunol"},{"key":"378_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/leu.2015.240","volume":"30","author":"H Jiang","year":"2016","unstructured":"Jiang, H. et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia 30, 399\u2013408 (2016).","journal-title":"Leukemia"},{"key":"378_CR35","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","volume":"21","author":"IS Nijhof","year":"2015","unstructured":"Nijhof, I. S. et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin. Cancer Res. 21, 2802\u20132810 (2015).","journal-title":"Clin. Cancer Res."},{"key":"378_CR36","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik, J. et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 384\u2013394 (2016).","journal-title":"Blood"},{"key":"378_CR37","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","volume":"128","author":"G An","year":"2016","unstructured":"An, G. et al. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood 128, 1590\u20131603 (2016).","journal-title":"Blood"},{"key":"378_CR38","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3389\/fimmu.2018.01822","volume":"9","author":"YT Tai","year":"2018","unstructured":"Tai, Y. T., Cho, S. F. & Anderson, K. C. Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1. Front. Immunol. 9, 1822 (2018).","journal-title":"Front. Immunol."},{"key":"378_CR39","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","volume":"120","author":"YT Tai","year":"2012","unstructured":"Tai, Y. T. et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120, 1877\u20131887 (2012).","journal-title":"Blood"},{"key":"378_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai, Y. T. et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28, 155\u2013165 (2014).","journal-title":"Leukemia"},{"key":"378_CR41","doi-asserted-by":"publisher","unstructured":"Cho, S. F. et al. BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma. Cancers (Basel) 12, 1473. https:\/\/doi.org\/10.3390\/cancers12061473 (2020).","DOI":"10.3390\/cancers12061473"},{"key":"378_CR42","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","volume":"19","author":"YT Tai","year":"2019","unstructured":"Tai, Y. T. & Anderson, K. C. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin. Biol. Ther. 19, 1143\u20131156 (2019).","journal-title":"Expert Opin. Biol. Ther."},{"key":"378_CR43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395, 132\u2013141 (2020).","journal-title":"Lancet"},{"key":"378_CR44","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells. Clin. Cancer Res. 24, 4006\u20134017 (2018).","journal-title":"Clin. Cancer Res."},{"key":"378_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk, M. B. et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7, 311\u2013321 (2015).","journal-title":"MAbs"},{"key":"378_CR46","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.4049\/jimmunol.1601473","volume":"198","author":"KLS Cleary","year":"2017","unstructured":"Cleary, K. L. S. et al. Antibody distance from the cell membrane regulates antibody effector mechanisms. J. Immunol. 198, 3999\u20134011 (2017).","journal-title":"J. Immunol."},{"key":"378_CR47","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng, X. et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin. Cancer Res. 23, 4290\u20134300 (2017).","journal-title":"Clin. Cancer Res."},{"key":"378_CR48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2010.030759","volume":"96","author":"MS van der Veer","year":"2011","unstructured":"van der Veer, M. S. et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96, 284\u2013290 (2011).","journal-title":"Haematologica"},{"key":"378_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.24","volume":"7","author":"L Zhang","year":"2017","unstructured":"Zhang, L. et al. Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu. Blood Cancer J. 7, e547 (2017).","journal-title":"Blood Cancer J"},{"key":"378_CR50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41375-019-0519-4","volume":"34","author":"I Akhmetzyanova","year":"2020","unstructured":"Akhmetzyanova, I. et al. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. Leukemia 34, 245\u2013256 (2020).","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00378-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:36:25Z","timestamp":1670250985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00378-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00378-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"3 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.C., B.R., A.W., K.V., H.A, G.B., Z.S., and J.R.M. are employees of Visterra Inc. N.M. serves on advisory boards to Millennium-Takeda, Celgene, and Novartis. K.C.A. serves on advisory boards Celgene, Millennium-Takeda, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Sanofi-Aventis and is a Scientific founder of OncoPep and C4 Therapeutics. All other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"110"}}